Article info
ABSTRACTS: POSTERS: Translational Research
SECOND-LINE THERAPY WITH TOPOTECAN AND PEGYLATED LIPOSOMAL DOXORUBICIN VS. TOPOTECAN ALONE IN PATIENTS WITH RECURRENT OVARIAN CANCER
Citation
SECOND-LINE THERAPY WITH TOPOTECAN AND PEGYLATED LIPOSOMAL DOXORUBICIN VS. TOPOTECAN ALONE IN PATIENTS WITH RECURRENT OVARIAN CANCER
Online issue publication
March 12, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2003 Blackwell Science Ltd.